Cargando…

Recent advances in drug delivery systems for targeting brain tumors

Brain tumor accounts for about 1.6% of incidence and 2.5% of mortality of all tumors, and the median survival for brain tumor patients is only about 20 months. The treatment for brain tumor still faces many challenges, such as the blood-brain barrier (BBB), blood-brain tumor barrier (BBTB), the over...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yi, Yue, Ping, Peng, Yao, Sun, Yuanyuan, Chen, Xing, Zhao, Ze, Han, Bingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828736/
https://www.ncbi.nlm.nih.gov/pubmed/36597214
http://dx.doi.org/10.1080/10717544.2022.2154409
_version_ 1784867334403391488
author Zhao, Yi
Yue, Ping
Peng, Yao
Sun, Yuanyuan
Chen, Xing
Zhao, Ze
Han, Bingjie
author_facet Zhao, Yi
Yue, Ping
Peng, Yao
Sun, Yuanyuan
Chen, Xing
Zhao, Ze
Han, Bingjie
author_sort Zhao, Yi
collection PubMed
description Brain tumor accounts for about 1.6% of incidence and 2.5% of mortality of all tumors, and the median survival for brain tumor patients is only about 20 months. The treatment for brain tumor still faces many challenges, such as the blood-brain barrier (BBB), blood-brain tumor barrier (BBTB), the overexpressed efflux pumps, the infiltration, invasion, high heterogeneity of tumor cells, drug resistance and immune escape caused by tumor microenvironment (TME) and cancer stem cells (CSC). This review attempts to clarify the challenges for multi-functional nano drug delivery systems (NDDS) to cross the BBB and target the cancer cells or organelles, and also provides a brief description of the different types of targeted multi-functional NDDS that have shown potential for success in delivering drugs to the brain. Further, this review also summarizes the research progress of multi-functional NDDS in the combination therapy of brain tumors from the following sections, the combination of chemotherapy drugs, chemotherapy-chemodynamic combination therapy, chemotherapy-immunization combination therapy, and chemotherapy-gene combination therapy. We also provide an insight into the recent advances in designing multi-functional NDDS for combination therapy.
format Online
Article
Text
id pubmed-9828736
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-98287362023-01-10 Recent advances in drug delivery systems for targeting brain tumors Zhao, Yi Yue, Ping Peng, Yao Sun, Yuanyuan Chen, Xing Zhao, Ze Han, Bingjie Drug Deliv Research Article Brain tumor accounts for about 1.6% of incidence and 2.5% of mortality of all tumors, and the median survival for brain tumor patients is only about 20 months. The treatment for brain tumor still faces many challenges, such as the blood-brain barrier (BBB), blood-brain tumor barrier (BBTB), the overexpressed efflux pumps, the infiltration, invasion, high heterogeneity of tumor cells, drug resistance and immune escape caused by tumor microenvironment (TME) and cancer stem cells (CSC). This review attempts to clarify the challenges for multi-functional nano drug delivery systems (NDDS) to cross the BBB and target the cancer cells or organelles, and also provides a brief description of the different types of targeted multi-functional NDDS that have shown potential for success in delivering drugs to the brain. Further, this review also summarizes the research progress of multi-functional NDDS in the combination therapy of brain tumors from the following sections, the combination of chemotherapy drugs, chemotherapy-chemodynamic combination therapy, chemotherapy-immunization combination therapy, and chemotherapy-gene combination therapy. We also provide an insight into the recent advances in designing multi-functional NDDS for combination therapy. Taylor & Francis 2023-01-03 /pmc/articles/PMC9828736/ /pubmed/36597214 http://dx.doi.org/10.1080/10717544.2022.2154409 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhao, Yi
Yue, Ping
Peng, Yao
Sun, Yuanyuan
Chen, Xing
Zhao, Ze
Han, Bingjie
Recent advances in drug delivery systems for targeting brain tumors
title Recent advances in drug delivery systems for targeting brain tumors
title_full Recent advances in drug delivery systems for targeting brain tumors
title_fullStr Recent advances in drug delivery systems for targeting brain tumors
title_full_unstemmed Recent advances in drug delivery systems for targeting brain tumors
title_short Recent advances in drug delivery systems for targeting brain tumors
title_sort recent advances in drug delivery systems for targeting brain tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828736/
https://www.ncbi.nlm.nih.gov/pubmed/36597214
http://dx.doi.org/10.1080/10717544.2022.2154409
work_keys_str_mv AT zhaoyi recentadvancesindrugdeliverysystemsfortargetingbraintumors
AT yueping recentadvancesindrugdeliverysystemsfortargetingbraintumors
AT pengyao recentadvancesindrugdeliverysystemsfortargetingbraintumors
AT sunyuanyuan recentadvancesindrugdeliverysystemsfortargetingbraintumors
AT chenxing recentadvancesindrugdeliverysystemsfortargetingbraintumors
AT zhaoze recentadvancesindrugdeliverysystemsfortargetingbraintumors
AT hanbingjie recentadvancesindrugdeliverysystemsfortargetingbraintumors